Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early intranasal medication administration in out-of-hospital cardiac arrest: Two randomized simulation trials.
Dowker SR, Downey ML, Majhail NK, Scott IG, Mathisson J, Rizk D, Trumpower B, Yake D, Williams M, Coulter-Thompson EI, Brent CM, Smith GC, Swor R, Berger DA, Rooney DM, Neumar RW, Friedman CP, Cooke JM, Missel AL. Dowker SR, et al. Among authors: rizk d. J Am Coll Emerg Physicians Open. 2024 Jan 21;5(1):e13100. doi: 10.1002/emp2.13100. eCollection 2024 Feb. J Am Coll Emerg Physicians Open. 2024. PMID: 38260004 Free PMC article.
Antineutrophil cytoplasmic antibody-associated vasculitis.
Konda R, Rajasekaran A, Rizk DV. Konda R, et al. Among authors: rizk dv. Curr Opin Nephrol Hypertens. 2024 May 27. doi: 10.1097/MNH.0000000000001004. Online ahead of print. Curr Opin Nephrol Hypertens. 2024. PMID: 38785128
Targeting the Endothelin A Receptor in IgA Nephropathy.
Kohan DE, Barratt J, Heerspink HJL, Campbell KN, Camargo M, Ogbaa I, Haile-Meskale R, Rizk DV, King A. Kohan DE, et al. Among authors: rizk dv. Kidney Int Rep. 2023 Aug 4;8(11):2198-2210. doi: 10.1016/j.ekir.2023.07.023. eCollection 2023 Nov. Kidney Int Rep. 2023. PMID: 38025243 Free PMC article. Review.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
247 results